S'abonner

The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes - 02/09/11

Doi : 10.1067/mob.2002.121073 
Charles R. Bauer, MDa a, Seetha Shankaran, MDb a, Henrietta S. Bada, MDc a, Barry Lester, PhDd a, Linda L. Wright, MDe a, Heidi Krause-Steinrauf, MSf a, Vincent L. Smeriglio, PhDg a, Loretta P. Finnegan, MDh a, Penelope L. Maza, PhDi a, Joel Verter, PhDf a
a From the aDepartment of Pediatrics, University of Miami School of Medicine, the bDepartment of Pediatrics, Wayne State University School of Medicine, the cDepartment of Pediatrics, Memphis College of Medicine, University of Tennessee, the dDepartment of Pediatrics, Women's and Infants Hospital, Brown University School of Medicine, the eNational Institute of Child Health and Human Development, the fBiostatistics Center, George Washington University, the gNational Institute on Drug Abuse, the hOffice of Research on Women's Health, National Institutes of Health, and the iAdministration on Children, Youth, and Families. 

Abstract

OBJECTIVE: Reports of maternal effects resulting from drug exposure during pregnancy are inconsistent. The Maternal Lifestyle Study (MLS) is a multicenter, prospective, observational study that was initiated to better define the effects of exposure to illicit drugs during pregnancy on the mother, fetus, and infant. METHODS: Between May 1993 and May 1995, of 19,079 mother-infant dyads that were screened after delivery for cocaine and opiate exposure at four clinical centers (Brown University, University of Miami, University of Tennessee, Memphis, and Wayne State University), 16,988 (89%) met eligibility criteria and 11,811 (70%) of those eligible agreed to participate in the study. Exposure was defined as an admission of use of cocaine or opiates or both or the presence of cocaine or opiate metabolites in meconium as determined by use of gas chromatography–mass spectroscopy assay. Nonexposure was defined as a negative drug use history by interview and a negative immunoassay screen. When exposure could not be confirmed, such as when meconium was not obtained or was inadequate for confirmatory analysis, the mother-infant dyad was excluded (n = 3184). RESULTS: Of the mothers who consented to participate, 50% were African American, 38% were married, 64% were Medicaid recipients, and 95% had at least one prenatal care visit (median, 10 visits). Significant differences (P < .01) between cocaine-opiate exposed (n = 1185) and nonexposed (n = 7442) mothers included race (African American: 74.6% and 47.0%, respectively), mean age (29.6 and 26.1 years, respectively), and polydrug use including any combination of alcohol, tobacco, and/or marijuana (93% and 42%, respectively). Odds ratios (99% CI) indicate that exposed mothers had a significantly higher risk(P < .001) of medical complications including syphilis 6.7 (4.8-9.6), gonorrhea 1.9 (1.3-3.0), and hepatitis 4.8 (2.6-8.91); psychiatric, nervous, and emotional disorders 4.0 (2.2-7.4); and abruptio placenta 2.3 (1.4-3.9). The odds of a positive test for human immunodeficiency virus were higher (available on 28% of the cohort) in the exposed group 8.2 (14.3-15.4). Seventeen cases of maternal acquired immunodeficiency syndrome (AIDS) were identified. Opiate exposure with its attendant needle use significantly increased the risk of hepatitis and AIDS. The number of hospitalizations during pregnancy did not differ between the exposure groups because 11% of patients in each group were hospitalized at least once. However, violence as a cause of hospitalization was more common in the cocaine-exposed group, 19.6 (2.7-144.7). CONCLUSION: This observational study confirmed many of the reported adverse social and serious medical perinatal complications of mothers exposed to cocaine or opiates during pregnancy. The overall prevalence of these risk outcomes was lower than has been reported previously. (Am J Obstet Gynecol 2002;186:487-95.)

Le texte complet de cet article est disponible en PDF.

 Supported by the National Institute of Child Health and Human Development through cooperative agreements (No. U10 HD 21397),a(No. U10 HD 21385),b(No. U10 HD 27856),c(No. U10 HD 27904),dand (No. U01 HD 19897),fand intra-agency agreements with the National Institute on Drug Abuse, Administration on Children, Youth and Families, and the Center for Substance Abuse Treatment. (CSAT)


© 2002  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 186 - N° 3

P. 487-495 - mars 2002 Retour au numéro
Article précédent Article précédent
  • What are pregnant women eating? Nutrient and food group differences by race
  • Anna Maria Siega-Riz, Lisa M. Bodnar, David A. Savitz
| Article suivant Article suivant
  • Oxytocin preparation stability in several common obstetric intravenous solutions
  • John W. Gard, James M. Alexander, Roger E. Bawdon, Jon T. Albrecht

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.